DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY. (4th December 2020)
- Record Type:
- Journal Article
- Title:
- DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY. (4th December 2020)
- Main Title:
- DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY
- Authors:
- Lafay-Cousin, Lucie
Lane, Adam
Schafer, Austin
Saab, Raya
Cheng, Sylvia
Bandopadhayay, Pratiti
Zaghloul, Mohamed
El-Ayadi, Motasem
Dorris, Kathleen
Packer, Roger
Kilburn, Lindsey
Minturn, Jane
Dodgshun, Andrew
Parkin, Sara
Lombardi, Mercedes Garcia
Cohen, Kenneth
Gass, David
Goldman, Stewart
Sandler, Eric
Warren, Katherine
Greiner, Robert
Gottardo, Nicholas
Dholaria, Hetal
Hassall, Tim
Coven, Scott
Hansford, Jordan
Samson, Yvan
Leary, Sarah
Bartels, Ute
Bouffet, Eric
Ma, Jie
Tinkle, Christopher
Monje-Deisseroth, Michelle
Fisher, Paul
Tsui, Karen
Ziegler, David
Chintagumpala, Murali
Gururangan, Sridharan
Wagner, Lars
Koschmann, Carl
DeWire-Schottmiller, Mariko
Leach, James
Jones, Blaise
Fuller, Christine
Drissi, Rachid
Chaney, Brooklyn
Black, Katie
Fouladi, Maryam
Strother, Douglas
… (more) - Abstract:
- Abstract: PURPOSE: To review data from DIPG Registry patients recorded to have received a second course of radiation therapy (rRT). METHODS: The International DIPG Registry was searched for patients with DIPG who were treated with a known dose of rRT. Doses of rRT, timing from initial diagnosis and primary radiation therapy (pRT), radiographic response to rRT and survival from diagnosis (OS) were evaluated. RESULTS: Sixty (11.2%) of 535 Registry patients underwent rRT; dose was provided for 44 patients. Median (range) data from those 44 revealed that rRT was given at 12 (2–65) months from initial diagnosis of DIPG and at 9.6 (1–61) months from completion of pRT at a dose of 26.7 (1.8–74) Gy. After completion of rRT, MRI showed response, progression, stable disease or was not available in 19, 8, 3 and 14 patients, respectively. Median PFS and OS were 11 and 18.1 months, respectively. 475 Registry patients did not undergo rRT; their ages, duration of symptoms, and primary treatment with or without chemotherapy were not significantly different from the rRT cohort. Median PFS and OS for the non-rRT patients were 6.9 and 10 months, respectively. rRT patients were more likely to have had radiographic evidence of tumor necrosis at diagnosis than non-rRT patients. CONCLUSIONS: Administration of rRT to patients with DIPG has been inconsistent with respect to timing and dose. Toxicity, response and quality of life data are incomplete, but survival appears to be lengthened with rRT.Abstract: PURPOSE: To review data from DIPG Registry patients recorded to have received a second course of radiation therapy (rRT). METHODS: The International DIPG Registry was searched for patients with DIPG who were treated with a known dose of rRT. Doses of rRT, timing from initial diagnosis and primary radiation therapy (pRT), radiographic response to rRT and survival from diagnosis (OS) were evaluated. RESULTS: Sixty (11.2%) of 535 Registry patients underwent rRT; dose was provided for 44 patients. Median (range) data from those 44 revealed that rRT was given at 12 (2–65) months from initial diagnosis of DIPG and at 9.6 (1–61) months from completion of pRT at a dose of 26.7 (1.8–74) Gy. After completion of rRT, MRI showed response, progression, stable disease or was not available in 19, 8, 3 and 14 patients, respectively. Median PFS and OS were 11 and 18.1 months, respectively. 475 Registry patients did not undergo rRT; their ages, duration of symptoms, and primary treatment with or without chemotherapy were not significantly different from the rRT cohort. Median PFS and OS for the non-rRT patients were 6.9 and 10 months, respectively. rRT patients were more likely to have had radiographic evidence of tumor necrosis at diagnosis than non-rRT patients. CONCLUSIONS: Administration of rRT to patients with DIPG has been inconsistent with respect to timing and dose. Toxicity, response and quality of life data are incomplete, but survival appears to be lengthened with rRT. Prospective clinical trials will elucidate benefits and risks of rRT. … (more)
- Is Part Of:
- Neuro-oncology. Volume 22(2020)Supplement 3
- Journal:
- Neuro-oncology
- Issue:
- Volume 22(2020)Supplement 3
- Issue Display:
- Volume 22, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 22
- Issue:
- 3
- Issue Sort Value:
- 2020-0022-0003-0000
- Page Start:
- iii301
- Page End:
- iii302
- Publication Date:
- 2020-12-04
- Subjects:
- Brain Neoplasms -- Periodicals
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481 - Journal URLs:
- http://neuro-oncology.dukejournals.org/ ↗
http://neuro-oncology.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/content?genre=journal&issn=1522-8517 ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/neuonc/noaa222.116 ↗
- Languages:
- English
- ISSNs:
- 1522-8517
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.288000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15502.xml